Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings

Medicines that are based on known molecules and are further developed to address healthcare needs and deliver relevant improvement for patients, healthcare professionals and/or payers are called value-added medicines (VAMs). The evaluation process of VAMs is heterogeneous across countries, and it has been primarily designed for originator pharmaceuticals with confirmatory evidence collected alongside pivotal clinical trials. There is a mismatch between evidence requirements …

Read the source article at resource-allocation.biomedcentral.com
2021-08-31 01:00:00